ICU sedation, delirium & recovery
Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study
Authors' conclusion
Remimazolam besylate appears to be an effective and safe agent for short-term deep sedation in critically ill patients.
Study context
- Population
- Critically ill intensive care unit (ICU) patients requiring deep sedation (Richmond Agitation and Sedation Scale (RASS) −4 or −5)
- Participants
- 30 vs 30
- Comparison
- Remimazolam besylate vs propofol for deep sedation
- Remimazolamn = 30
- Propofoln = 30reference
- Primary endpoint
- Percentage of time within target sedation range without rescue sedation
Methodological detailssingle-center, prospective, pilot
- Single-center
- Prospective
- Pilot
Primary result
As reported in the abstract
Time at target RASS
Secondary outcomes
Sedation depth during intervention (both groups)
- Median (IQR) RASS score
- - 5.0 (- 5.0, - 4.0)
- Median (IQR) Narcotrend Index (NI) value
- 29.0 (21.0, 37.0)
Ventilator-free hours within 7 days, successful extubation, ICU LOS, 28-day mortality
- No significant differences between groups
Safety
Hypotension
P > 0.05
Bradycardia
- No patient experienced bradycardia
Original publication
Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study. Crit Care. Published 4 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →